Primary immunodeficiencies: a decade of shifting paradigms, the current status and the emergence of cutting-edge therapies and diagnostics

References

• Al-Herz W, Bousfiha A, Casanova J-L, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2011;8(2):54
   Google Scholar
• Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res 2008;28(2B):1263-9
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C. Common variable immunodeficiency. Curr Allergy Asthma Rep 2001;1:421-9
   PubMedGoogle Scholar
• Smith CI, Vihinen M. lmmunodeficiency mutation databases-A new research tool. Immunol Today 1996;17:495-6
   PubMedGoogle Scholar
• Vihinen M, Arredondo-Vega FX, Casanova J-L, et al. 4. Primary immunodeficiency mutation databases. Adv Genet 2001;43:103-88
   PubMed Web of Science ®Google Scholar
• Picard C, Fischer A. Contribution of high-throughput DNA sequencing to the study of primary immunodeficiencies. Eur J Immunol 2014;44(10):2854-61
   PubMed Web of Science ®Google Scholar
• Chou J, Ohsumi TK, Geha RS. Use of whole exome and genome sequencing in the identification of genetic causes of primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2012;12(6):623-8
   PubMed Web of Science ®Google Scholar
• Weiss MM, Zwaag B, Jongbloed JD, et al. Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: a national collaborative study of dutch genome diagnostic laboratories. Hum Mutation 2013;34(10):1313-21
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21(2):137-48
   PubMed Web of Science ®Google Scholar
• Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol 2011;127(6):1329-41. e1322
   PubMed Web of Science ®Google Scholar
• Chinen J, Notarangelo LD, Shearer WT. Advances in basic and clinical immunology in. 2013. J Allergy Clin Immunol 2014;133(4):967-76
   PubMed Web of Science ®Google Scholar
• Maggina P, Gennery AR. Classification of primary immunodeficiencies: need for a revised approach? J Allergy Clin Immunol 2013;131(2):292-4
   PubMed Web of Science ®Google Scholar
• Ochs H HD. Primary immunodeficiency disorders: general classification, new molecular insights, and practical approach to diagnosis and treatment. Ann Allergy Asthma Immunol 2014;112(2014):489-95
   PubMedGoogle Scholar
• Hayakawa H, Iwata T, Yata J, Kobayashi N. Primary immunodeficiency syndrome in Japan. I. Overview of a nationwide survey on primary immunodeficiency syndrome. J Clin Immunol 1981;1(1):31-9
   PubMed Web of Science ®Google Scholar
• Rezaei N, Mohammadinejad P, Aghamohammadi A. The demographics of primary immunodeficiency diseases across the unique ethnic groups in Iran, and approaches to diagnosis and treatment. Anna NY Acad Sci 2011;1238(1):24-32
   PubMedGoogle Scholar
• Movahedi M, Aghamohammadi A, Rezaei N, et al. Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry. Int Arch Allergy Immunol 2004;134(3):253-9
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Moin M, Rezaei N. History of primary immunodeficiency diseases in Iran. Iranian J Ped 2010;20(1):16
   PubMed Web of Science ®Google Scholar
• Notarangelo LD. Partial defects of T-cell development associated with poor T-cell function. J Allergy Clin Immunol 2013;131(5):1297-305
   PubMed Web of Science ®Google Scholar
• Al-Herz W, Al-Mousa H. Combined immunodeficiency: the Middle East experience. J Allergy Clin Immunol 2013;131(3):658-60
   PubMed Web of Science ®Google Scholar
• Glocker E-O, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. New Engl J Med 2009;361(18):1727-35
   PubMed Web of Science ®Google Scholar
• Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. 3 New Engl J Med 2007;57(16):1608-19
   Google Scholar
• Norouzi S, Aghamohammadi A, Mamishi S, et al. Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. J Infection 2012;64(6):543-54
   PubMed Web of Science ®Google Scholar
• Lindegren ML, Kobrynski L, Rasmussen SA, et al. Applying public health strategies to primary immunodeficiency diseases. Potential App Genet Dis Recommend Rep 2004;53:1-29
   Google Scholar
• Kwan A, Church JA, Cowan MJ, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol 2013;132(1):140-50. e147
   PubMed Web of Science ®Google Scholar
• McGhee SA, Stiehm ER, Cowan M, et al. Two-tiered universal newborn screening strategy for severe combined immunodeficiency. Mol Genet Metabolism 2005;86(4):427-30
   PubMed Web of Science ®Google Scholar
• Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 2005;115(2):391-8
   PubMed Web of Science ®Google Scholar
• Puck JM. Population-based newborn screening for severe combined immunodeficiency: steps toward implementation. J Allergy Clin Immunol 2007;120(4):760-8
   PubMed Web of Science ®Google Scholar
• Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014;312(7):729-38
   PubMed Web of Science ®Google Scholar
• Dvorak C, Cowan M. Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplant 2007;41(2):119-26
   PubMed Web of Science ®Google Scholar
• Hendaus MA, Alhammadi A, Adeli MM, Al-Yafei F. The value of family history in diagnosing primary immunodeficiency disorders. Case Rep Pediatrics 2014;2014:516256
   PubMedGoogle Scholar
• Gaspar H, Lester T, Levinsky R, Kinnon C. Bruton’s tyrosine kinase expression and activity in X-linked agammaglobulinaemia (XLA): the use of protein analysis as a diagnostic indicator of XLA. Clini Experi Immunol 1998;111(2):334-8
   PubMed Web of Science ®Google Scholar
• Rodriguez C, d’Audigier C, Bertrand V. Validation of a Bruton’s disease genetic analysis method. Ann Biol Clin (Paris) 2005;64(5):445-9
   Web of Science ®Google Scholar
• Ochs HD, Smith CE, Puck JM. Primary Immunodeficiency Diseases: A Molecular and Cellular Approach. Oxford University Press; USA: 2013
   Google Scholar
• Hitzig W, Biro Z, Bosch H, Huser H. Agammaglobulinemia & alymphocytosis with atrophy of lymphatic tissue. Helv Paediatr Acta 1958;13(6):551-85
   PubMedGoogle Scholar
• Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 1993;262(5141):1877-80
   PubMed Web of Science ®Google Scholar
• Pannicke U, Hönig M, Hess I, et al. Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nature Genet 2008;41(1):101-5
   PubMed Web of Science ®Google Scholar
• Lagresle-Peyrou C, Six EM, Picard C, et al. Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nature Genet 2008;41(1):106-11
   PubMed Web of Science ®Google Scholar
• Villard J, Masternak K, Lisowska-Grospierre B, et al. MHC class II deficiency: a disease of gene regulation. Medicine 2001;80(6):405-18
   PubMed Web of Science ®Google Scholar
• Vetrie D, Voiechovskyli I, Siderasi P, et al. The gene involved in X-linked agammaglobulinemia is a member of the. Nature 1993;361
   PubMed Web of Science ®Google Scholar
• Kwan S-P, Lehner T, Hagemann T, et al. Localization of the gene for the Wiskott-Aldrich syndrome between two flanking markers, TIMP and DXS255, on Xp11. 22–Xp11. 3. Genomics 1991;10(1):29-33
   PubMed Web of Science ®Google Scholar
• Schatz DG, Oettinger MA, Baltimore D. The V (D) J recombination activating gene, Rag-1. cell 1989;59(6):1035-48
   PubMed Web of Science ®Google Scholar
• Sanger F, Air GM, Barrell BG, et al. Nucleotide sequence of bacteriophage phi X174 DNA. Nature 1977;265:687-95
   PubMed Web of Science ®Google Scholar
• Smith LM, Sanders JZ, Kaiser RJ, et al. Fluorescence detection in automated DNA sequence analysis. Nature 1986;321(6071):674-9
   PubMed Web of Science ®Google Scholar
• Cuvelier GD, Schultz KR, Davis J, et al. Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency. Clin Immunol 2009;131(2):179-88
   PubMed Web of Science ®Google Scholar
• Wheeler DA, Srinivasan M, Egholm M, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 2008;452(7189):872-6
   PubMed Web of Science ®Google Scholar
• Parvaneh N, Casanova J-L, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol 2013;131(2):314-23
   PubMed Web of Science ®Google Scholar
• Snow AL, Xiao W, Stinson JR, et al. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exper Med 2012;209(12):2247-61
   PubMed Web of Science ®Google Scholar
• Stepensky P, Keller B, Buchta M, et al. Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects. J Allergy Clin Immunol 2013;131(2):477-85. e471
   PubMed Web of Science ®Google Scholar
• Greil J, Rausch T, Giese T, et al. Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency. J Allergy Clin Immunol 2013;131(5):1376-83. e1373
   PubMed Web of Science ®Google Scholar
• Uzel G, Sampaio EP, Lawrence MG, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome. J Allergy Clin Immunol 2013;131(6):1611-23. e1613
   PubMed Web of Science ®Google Scholar
• Metzker ML. Sequencing technologies—the next generation. Nature Rev Genet 2009;11(1):31-46
   PubMed Web of Science ®Google Scholar
• Nowrousian M. Next-generation sequencing techniques for eukaryotic microorganisms: sequencing-based solutions to biological problems. Eukaryot Cell 2010;9(9):1300-10
   PubMedGoogle Scholar
• Harakalova M, Mokry M, Hrdlickova B, et al. Multiplexed array-based and in-solution genomic enrichment for flexible and cost-effective targeted next-generation sequencing. Nature Prot 2011;6(12):1870-86
   PubMed Web of Science ®Google Scholar
• Majewski J, Schwartzentruber J, Lalonde E, et al. What can exome sequencing do for you? J Med Genet 2011;48(9):580-9
   PubMed Web of Science ®Google Scholar
• Byun M, Abhyankar A, Lelarge V, et al. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. J Exper Med 2010;207(11):2307-12
   PubMed Web of Science ®Google Scholar
• Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011;118(10):2656-8
   PubMed Web of Science ®Google Scholar
• Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011;118(10):2653-5
   PubMed Web of Science ®Google Scholar
• Li F-Y, Chaigne-Delalande B, Kanellopoulou C, et al. Signaling role for Mg2+ revealed by immunodeficiency due to loss of MagT1. Nature 2012;475(7357):471
   Google Scholar
• Liu L, Okada S, Kong X-F, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exper Med 2011;208(8):1635-48
   PubMed Web of Science ®Google Scholar
• Van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011;365(1):54-61
   PubMed Web of Science ®Google Scholar
• Conley ME, Dobbs AK, Quintana AM, et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K. J Exper Med 2012;209(3):463-70
   PubMed Web of Science ®Google Scholar
• Bolze A, Mahlaoui N, Byun M, et al. Ribosomal protein SA haploinsufficiency in humans with isolated congenital asplenia. Science 2013;340(6135):976-8
   PubMed Web of Science ®Google Scholar
• Angulo I, Vadas O, Garçon F, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 2013;342(6160):866-71
   PubMed Web of Science ®Google Scholar
• Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI (3) K catalytic subunit p110 [delta] result in T cell senescence and human immunodeficiency. Nat Immunol 2014;15(1):88-97
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011;365(7):620-8
   PubMed Web of Science ®Google Scholar
• Kitamura A, Maekawa Y, Uehara H, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest 2011;121(10):4150-60
   PubMed Web of Science ®Google Scholar
• Ombrello MJ, Remmers EF, Sun G, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012;366(4):330-8
   PubMed Web of Science ®Google Scholar
• Alangari A, Alsultan A, Adly N, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol 2012;130(2):481-8. e482
   PubMed Web of Science ®Google Scholar
• Bogunovic D, Boisson-Dupuis S, Casanova J-L. ISG15: leading a double life as a secreted molecule. Exper Mol Med 2013;45(4):e18
   PubMedGoogle Scholar
• Boisson B, Laplantine E, Prando C, et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012;13(12):1178-86
   PubMed Web of Science ®Google Scholar
• Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Meth 2010;7(4):248-9
   PubMed Web of Science ®Google Scholar
• Pan-Hammarström Q, Salzer U, Du L, et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nature Genet 2007;39(4):429
   PubMed Web of Science ®Google Scholar
• Holliday R. Epigenetics: a historical overview. Epigenetics 2005;1(2):76-80
   Web of Science ®Google Scholar
• Notarangelo LD, Sorensen R. Is it necessary to identify molecular defects in primary immunodeficiency disease? J Allergy Clin Immunol 2008;122(6):1069-73
   PubMed Web of Science ®Google Scholar
• Abolhassani H, Sagvand BT, Shokuhfar T, et al. A review on guidelines for management and treatment of common variable immunodeficiency. Expert Rev Clin Immunol 2013;9(6):561-75
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Allahverdi A, Abolhassani H, et al. Comparison of pulmonary diseases in common variable immunodeficiency and X-linked agammaglobulinaemia. Respirology 2010;15(2):289-95
   PubMed Web of Science ®Google Scholar
• Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 2012;32(6):1180-92
   PubMed Web of Science ®Google Scholar
• Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. 7 Adverse reactions of prophylactic intravenous immunoglobulin; A 13-year experience with 3004 infusions in iranian patients with primary immunodeficiency diseases. J Invest Allergol Clin Immunol 2009;19(2):139
   PubMed Web of Science ®Google Scholar
• Rezaei N, Abolhassani H, Aghamohammadi A, Ochs HD. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol 2011;7(3):301-16
   PubMed Web of Science ®Google Scholar
• Maarschalk-Ellerbroek L, Hoepelman I, Ellerbroek P. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents 2011;37(5):396-404
   PubMed Web of Science ®Google Scholar
• Brinker KA, Silk HJ. Common variable immune deficiency and treatment with intravenous immunoglobulin during pregnancy. Anna Allergy Asthma Immunol 2012;108(6):464-5
   PubMed Web of Science ®Google Scholar
• Sagvand BT, Mirminachi B, Abolhassani H, et al. IgG anti-IgA antibodies in paediatric antibody-deficient patients receiving intravenous immunoglobulin. Allergol Immunopathol (Madr) 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Van der Heijden J, Geissler J, van Mirre E, et al. A novel splice variant of FcγRIIa: A risk factor for anaphylaxis in patients with hypogammaglobulinemia. J Allergy Clin Immunol 2013;131(5):1408-16. e1405
   PubMed Web of Science ®Google Scholar
• JG Peter HC. Immunoglobulin replacement therapy for primary immunodeficiencies. Immunotherapy 2014;6(7):853-69
   PubMed Web of Science ®Google Scholar
• Chan B, Wara D, Bastian J, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol 2005;117(2):133-43
   PubMed Web of Science ®Google Scholar
• Horn B, Cowan MJ. Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects. J Allergy Clin Immunol 2013;131(5):1306-11
   PubMed Web of Science ®Google Scholar
• Güngör T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014;383(9915):436-48
   PubMed Web of Science ®Google Scholar
• Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010;126(3):602-10. e611
   PubMed Web of Science ®Google Scholar
• Pai S-Y, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med 2014;371(5):434-46
   PubMed Web of Science ®Google Scholar
• Qasim W, Gennery AR. Gene therapy for primary immunodeficiencies: current status and future prospects. Drugs 2014;74(9):963-9
   PubMed Web of Science ®Google Scholar
• Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase–deficient severe combined immunodeficiency. Blood 2012;120(17):3615-24
   PubMed Web of Science ®Google Scholar
• Titman P, Pink E, Skucek E, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 2008;112(9):3907-13
   PubMed Web of Science ®Google Scholar
• Garrod KR, Liu F-C, Forrest LE, et al. NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity. J Immunol 2010;184(5):2329-36
   PubMed Web of Science ®Google Scholar
• Dvorak C HG-Y, Horn B, Dunn E, et al. Megadose CD341cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haploidentical nonmyeloablative transplantation. Biol Blood Marrow Transplant 2008;14:1125-33
   PubMed Web of Science ®Google Scholar
• Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatrics 2009;155(6):834-40. e831
   PubMed Web of Science ®Google Scholar
• Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009;113(17):4114-24
   PubMed Web of Science ®Google Scholar
• Gruhn B, Seidel J, Zintl F, et al. Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure. Orphanet J Rare Dis 2007;2:5
   PubMedGoogle Scholar
• Cavazzana-Calvo M, Carlier F, Le Deist F, et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell–immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 2007;109(10):4575-81
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010;363(4):355-64
   PubMed Web of Science ®Google Scholar
• Renella R, Picard C, Neven B, et al. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections. Br J Haematol 2006;134(5):510-16
   PubMed Web of Science ®Google Scholar
• Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006;295(5):508-18
   PubMed Web of Science ®Google Scholar
• Antoine C, Müller S, Cant A, et al. European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003;361(9357):553-60
   PubMed Web of Science ®Google Scholar
• Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008;111(1):439-45
   PubMed Web of Science ®Google Scholar
• Roberts JL, Lengi A, Brown SM, et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood 2004;103(6):2009-18
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Slatter M, Chapman C, et al. Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency. Bone Marrow Transplant 2005;36(4):295-9
   PubMed Web of Science ®Google Scholar
• Touzot F, Neven B, Dal-Cortivo L, et al. CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study. J Allergy Clin Immunol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Pai S-Y, Cowan MJ. CURRENT OPINION Stem cell transplantation for primary immunodeficiency diseases: the North American experience. Curr Opin Allergy Clin Immunol 2014;14:000-0
   Web of Science ®Google Scholar
• Brown L, Xu-Bayford J, Allwood Z, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood 2011;117(11):3243-6
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 2007;117(6):1456-65
   PubMed Web of Science ®Google Scholar
• Pai S, DeMartiis D, Forino C, et al. Stem cell transplantation for the Wiskott–Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 2006;38(10):671-9
   PubMed Web of Science ®Google Scholar
• Haddad E, Leroy S, Buckley RH. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? J Allergy Clin Immunol 2013;131(4):994-1000
   PubMed Web of Science ®Google Scholar
• Hönig M, Albert MH, Schulz A, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 2007;109(8):3595-602
   PubMed Web of Science ®Google Scholar
• Sarzotti-Kelsoe M, Win CM, Parrott RE, et al. Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood 2009;114(7):1445-53
   PubMed Web of Science ®Google Scholar
• Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005;105(2):879-85
   PubMed Web of Science ®Google Scholar
• Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency (PID): UK experience. Blood 2011;117(16):4367-75
   PubMed Web of Science ®Google Scholar
• Laffort C LD, Favre M, Debre M, et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 2004;363:2051-4
   PubMed Web of Science ®Google Scholar
• Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 2011;46(12):1495-502
   PubMed Web of Science ®Google Scholar
• Touzot F, Moshous D, Cros G, et al. Circulating endothelial cells as markers of endothelial dysfunction during hematopoietic stem cell transplantation for pediatric primary immunodeficiency. J Allergy Clini Immunol 2014;134(5):1203-6
   PubMed Web of Science ®Google Scholar
• Griffith LM, Cowan MJ, Notarangelo LD, et al. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 2014;133(2):335-47. e311
   PubMed Web of Science ®Google Scholar
• Haddad E, Allakhverdi Z, Griffith LM, et al. Survey on retransplantation criteria for patients with severe combined immunodeficiency. J Allergy Clin Immunol 2014;133(2):597-9
   PubMed Web of Science ®Google Scholar
• Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell–depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998;91(10):3646-53
   PubMed Web of Science ®Google Scholar
• Ozyurek E, Cowan M, Koerper M, et al. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant 2008;42(2):83-91
   PubMed Web of Science ®Google Scholar
• Triplett BM, Wang C, Yang J, et al. Effects of conditioning regimens and T cell depletion in hematopoietic cell transplantation for primary immune deficiency. Biol Blood Marrow Transplant 2012;18(12):1911-20
   PubMed Web of Science ®Google Scholar
• Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296(5577):2410-13
   PubMed Web of Science ®Google Scholar
• Candotti F. Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases. Int J Hematol 2014;99(4):383-92
   PubMed Web of Science ®Google Scholar
• Schuetz C, Neven B, Dvorak CC, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood 2014;123(2):281-9
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011;3(97):97 -79
   Web of Science ®Google Scholar
• Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118(9):3143-50
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118(9):3132-42
   PubMed Web of Science ®Google Scholar
• Thornhill SI, Schambach A, Howe SJ, et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 2008;16(3):590-8
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase–deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011;3(97):97 -80
   Web of Science ®Google Scholar
• Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360(5):447-58
   PubMed Web of Science ®Google Scholar
• Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clinical Invest 2007;117(8):2233-40
   PubMed Web of Science ®Google Scholar
• Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009. an international collaborative study. Blood 2011;118(6):1675-84
   PubMed Web of Science ®Google Scholar
• Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013;341(6148):1233151
   PubMed Web of Science ®Google Scholar
• Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12(4):401-9
   PubMed Web of Science ®Google Scholar
• van Til NP, Sarwari R, Visser TP, et al. Recombination-activating gene 1 (Rag1)–deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. J Allergy Clin Immunol 2014;133(4):1116-23
   PubMed Web of Science ®Google Scholar
• Brown MP, Topham DJ, Sangster MY, et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med 1998;4(11):1253-60
   PubMed Web of Science ®Google Scholar
• Bauer TR, Allen JM, Hai M, et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 2007;14(1):93-7
   PubMed Web of Science ®Google Scholar
• Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013;8(11):2281-308
   PubMed Web of Science ®Google Scholar
• Wood AJ, Lo T-W, Zeitler B, et al. Targeted genome editing across species using ZFNs and TALENs. Science 2011;333(6040):307-7
   PubMed Web of Science ®Google Scholar
• Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007;25(11):1298-306
   PubMed Web of Science ®Google Scholar
• McLean-Tooke A, Barge D, Spickett G, Gennery A. Flow cytometric analysis of TCR Vβ repertoire in patients with 22q11. 2 deletion syndrome. Scand J Immunol 2011;73(6):577-85
   PubMed Web of Science ®Google Scholar
• Moraes-Vasconcelos D, Costa-Carvalho B, Torgerson T, Ochs H. Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin Immunol 2008;28(1):11-19
   Google Scholar
• Adriani M, Aoki J, Horai R, et al. Impaired in vitro regulatory T cell function associated with Wiskott–Aldrich syndrome. Clinical immunology 2007;124(1):41-8
   PubMed Web of Science ®Google Scholar
• Kanai T, Jenks J, Nadeau KC. The STAT5b pathway defect and autoimmunity. Front Immunol 2012;3:234
   PubMed Web of Science ®Google Scholar
• Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 2002;99(8):2694-702
   PubMed Web of Science ®Google Scholar
• Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005;25(1):57-62
   PubMed Web of Science ®Google Scholar
• Lopes-da-Silva S, Rizzo LV. Autoimmunity in common variable immunodeficiency. J Clin Immunol 2008;28(1):46-55
   Google Scholar
• Goyal R, Bulua AC, Nikolov NP, et al. Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders. Curr Opin Rheumatol 2009;21(1):78
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev 2002;16(1):61-4
   PubMed Web of Science ®Google Scholar
• Warnatz K, Wehr C, Dräger R, et al. Expansion of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. Immunobiology 2002;206(5):502-13
   PubMed Web of Science ®Google Scholar
• Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine 2004;83(4):254-63
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008;28(1):42-5
   Web of Science ®Google Scholar
• Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev 2006;5(2):156-9
   PubMed Web of Science ®Google Scholar
• Bonduel M, Zelazko M, Figueroa C, et al. Successful treatment of autoimmune hemolytic anemia with rituximab in a child with severe combined immunodeficiency following nonidentical T-cell-depleted bone marrow transplantation. Bone Marrow Transplant 2005;35(8):819-21
   PubMed Web of Science ®Google Scholar
• Kim J, Thrasher A, Jones A, et al. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br J Haematol 2007;138(1):94-6
   PubMed Web of Science ®Google Scholar
• Hennig C, Baumann U, Ilginus C, et al. Successful treatment of autoimmune and lymphoproliferative complications of patients with intrinsic B-cell immunodeficiencies with Rituximab. Br J Haematol 2010;148(3):445-8
   PubMed Web of Science ®Google Scholar
• Shamsian BS, Mansouri D, Pourpak Z, et al. Autosomal recessive chronic granulomatous disease, IgA deficiency and refractory autoimmune thrombocytopenia responding to Anti-CD20 monoclonal antibody. Iran J Allergy Asthma Immunol 2008;7(3):181-4
   PubMed Web of Science ®Google Scholar
• Osnes LT, Nakken B, Bodolay E, Szodoray P. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies—novel tool for diagnostics and patient follow-up. Autoimmun Rev 2013;12(10):967-71
   PubMed Web of Science ®Google Scholar
• Puel A, Döffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010;207(2):291-7
   PubMed Web of Science ®Google Scholar
• Kilic SS. Anti-tumour necrosis factor-alpha treatment of juvenile idiopathic arthritis in a patient with common variable immunodeficiency. J Trop Pediatr 2005;51:194-5
   PubMed Web of Science ®Google Scholar
• Nos P, Bastida G, Beltran B, et al. Crohn’s disease in common variable immunodeficiency: treatment with antitumor necrosis factor alpha. Am J Gastroenterol 2006;101(9):2165-6
   PubMed Web of Science ®Google Scholar
• Kanai T, Watanabe M. Clinical application of human CD4+ CD25+ regulatory Tcells for the treatment of inflammatory bowel diseases. Expert Opin Biol Ther 2005;5(4):451-62
   PubMed Web of Science ®Google Scholar
• Eapen M, DeLaat C, Baker K, et al. Hematopoietic cell transplantation for Chediak–Higashi syndrome. Bone Marrow Transplant 2007;39(7):411-15
   PubMed Web of Science ®Google Scholar